Announcements
- Akari Therapeutics Announces Interim CEO Employment Contract Demonstrating Alignment with Shareholders
- Akari Therapeutics Secures $7.6 Million in Upsized Financing Round
- Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights
- Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics
- Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity
- Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024
- Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights
- Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit
- Akari Therapeutics Reports First Half 2023 Financial Results and Highlights
- Akari Therapeutics to Present at Emerging Growth Conference
More ▼
Key statistics
As of last trade, Akari Therapeutics PLC (CLA:FRA) traded at 1.87, 97.88% above the 52 week low of 0.945 set on Apr 19, 2024.
52-week range
Open | 1.87 |
---|---|
High | 1.87 |
Low | 1.87 |
Bid | 1.87 |
Offer | 2.04 |
Previous close | 1.70 |
Average volume | 0.00 |
---|---|
Shares outstanding | 396.18k |
Free float | 330.01k |
P/E (TTM) | -- |
Market cap | 13.58m USD |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of Jun 06 2024 07:10 BST.
More ▼